MEDI573 in Metastatic Breast Cancer

Investigator: Angel Rodriguez, MD

Study Coordinator: Maria Salazar

Status: Open Not Enrolling Number: NCT01446159

Phone: 713.441.6011

IRB Number: Pro00007421


This is a Phase 1b/2, multicenter, open-label study to evaluate the safety, tolerability, antitumor activity, and pharmacology of MEDI-573 in combination with an AI in adult subjects with HR+, HER2-negative MBC. This study has 2 phases: a dose-evaluation phase (Phase 1b) and a randomization phase (Phase 2).
More to Explore